Financial Market Analysis & Investment Research Partly open
Pfizer (PFE) – 7% dividend amid declining profits and +143.1%
Pfizer (PFE), analysis from July: business model, patent expirations, the Metsera acquisition and the obesity market, the agreement with the U.S. administration, debt burden, valuation multiples, ownership structure and dividend policy, plus the technical picture in gold and in nominal terms. The key question: what actually holds the share price in place, the dividend or the business itself.
Already subscribed to «Financial Market Analysis & Investment Research»? Then sign in to read it. Sign in
Full version
The closed part follows
The full material is available with the «Financial Market Analysis & Investment Research 42$» subscription, or as a single view for $10.
- the full set of indicators and market factors;
- an interpretation of the current picture;
- conclusions and the signals that follow.
Sign in or register — then you can buy this material separately.